Towards Precision Medicine in Diabetes and Related Complications

Guest Editor:

Dr. Claudia Menzaghi
Research Unit of Diabetes and Endocrine Diseases, Scientific Institute "Casa Sollievo della Sofferenza", Viale Padre Pio, 71013 San Giovanni Rotondo, Italy

Deadline for manuscript submissions:
closed (10 June 2023)

Message from the Guest Editor

Diabetes increases the risk of premature mortality and morbidity as a result of multisystem complications during the lifelong disease course. Due to the epidemic proportion that diabetes is assuming, thus greatly contributing to an increase in economic, social and human costs worldwide. To tackle such a burden, the development of precision medicine approaches to predict the most high-risk patients to be targeted with the most aggressive, expensive and burdensome prevention strategies is mandatory.

The use of "omics" information leading to the discovery of novel biomarkers and their integration in prediction models that incorporate data from accurate phenotyping would help clinicians to stratify patients' individual risk in order to choose the best follow-up and treatment strategies so as to maximize their effectiveness and minimize their costs.

It aims to highlight some of the latest studies in the field of "omics", in the application of precision medicine for people with diabetes and coincidentally in addressing pathogenic pathways that are either unknown or poorly understood and that can eventually become the target of new treatments.

mdpi.com/si/91487

Special issue

Editor-in-Chief

Prof. Dr. David Alan Rizzieri
1. Novant Health Cancer Institute, Winston-Salem, NC 27103, USA
2. Division of Hematologic Malignancies and Cellular Therapy, Duke University, Durham, NC 27710, USA

Message from the Editor-in-Chief

Journal of Personalized Medicine (*JPM*; ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. *JPM* publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, 'omics association analysis). *JPM* is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.
High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, and other databases.
Journal Rank: JCR - Q1 (Medicine, General and Internal) / CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us